Which country is Upadacitinib available in?

Upadacitinib (Upadacitinib) is a new JAK inhibitor developed by AbbVie in the United States. It is used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other diseases. The drug is marketed in many countries, including the United States, Europe, Japan, etc. In China, upadatinib has been approved by the National Medical Products Administration and has been approved for the treatment of relevant indications.

Upadatinib, also known as an immunomodulatory and disease-modifying antirheumatic drug (DMARD), is specifically designed to be a highly selective competitive inhibitor of the adenosine triphosphate binding pocket in JAK1. Upadatinib was shown to have a selectivity of 42 for JAK1 versus JAK2, a selectivity of 133 for JAK1 versus JAK3, and a selectivity of 194 for JAK1 versus TYK2 in cellular assays. Upadatinib has a half-life of 4 hours and is metabolized in the liver mainly by cytochrome P450 (CYP3A4) and secondarily by CYP2D6.

The original drug Upatinib, which is marketed in China, has also entered the scope of Class B medical insurance, and can only be reimbursed for eligible patients. Specifications The price of each box of 15mg*28 tablets may be around 3,000 yuan. The European version of the original drug sold overseas is priced at more than 20,000 yuan for 15mg*30 tablets (the price may fluctuate due to exchange rates), which is expensive. Cheaper upadatinib generic drugs are also sold overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 15mg*30 tablets produced by Bangladesh pharmaceutical factory is around 900 yuan (the price may fluctuate due to the exchange rate).